Results from the study demonstrated that combining anti-VEGF medications with AGVI resulted in superior outcomes compared to AGVI alone, including reduced postoperative IOP, decreased incidence of postoperative hyphema, diminished use of postoperative anti-glaucoma medications, and decreased intraocular VEGF levels. This evidence concerns the gene VEGFA and Hyphema.